One step closer to a cure for preeclampsia? Boosting the natural affinity of VEGF (vascular endothelial growth factor) to sFlt (soluble fms-like tyrosine kinase)-1

Bibliographic Details
Main Authors:	Cerdeira, AS, Vatish, M, Lecarpentier, E
Format:	Journal article
Language:	English
Published:	Lippincott, Williams & Wilkins 2020

The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial
by: Kifle, MM, et al.
Published: (2022)

The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial
by: Meron M. Kifle, et al.
Published: (2022-06-01)

Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment
by: Natalie J. Hannan, et al.
Published: (2017-05-01)

Differences in levelFms-Like Tyrosine Kinase-1 (sFlt-1), soluble Endoglin (s-Eng), and Placental Growth Factor (PIGF) between Early Onset Preeclampsia and Late Onset Preeclampsia
by: Lita Nafratilova, et al.
Published: (2018-10-01)

The soluble fms-like tyrosin kinase-1 (sFLT-1) to placental growth factor (PIGF) ratio as a possible indicator for the severity of preeclampsia - single institution experience
by: Andrijana Müller, et al.
Published: (2019-02-01)

Altered Level of Soluble fms-like Tyrosine Kinase 1 (sFlt1) and Hypoxia Inducible Factor-1alpha (HIF-1alpha) in Normotensive Pregnancy and Preeclampsia
by: John Wantania, et al.
Published: (2013-08-01)

Performance of sFlt-1/PlGF ratio ≥85 for ruling in preeclampsia within 4 weeks
by: Cerdeira, AS, et al.
Published: (2020)

Human umbilical cord mesenchymal stem cell derived exosomes (HUCMSC-exos) recovery soluble fms-like tyrosine kinase-1 (sFlt-1)-induced endothelial dysfunction in preeclampsia
by: Xinwen Chang, et al.
Published: (2023-08-01)

Serum heme oxygenase 1 (HO-1), soluble FMS like tyrosine kinase (sFlt-1) level, and neonatal outcome in early onset, late onset preeclampsia, and normal pregnancy
by: Muhammad Ilham Aldika Akbar, et al.
Published: (2018-10-01)

Use of serum and urinary soluble sFlt-1 and PLGF in the diagnosis of preeclampsia
by: Ping Tang, et al.
Published: (2017-01-01)

Prognostic value of serum soluble FMS-like tyrosine kinase (sFlt-1) levels in pre-eclampsia and eclampsia; a prospective cohort study
by: Ahmed M. Abbas, et al.
Published: (2018-07-01)

Predictive accuracy of soluble FMS-like tyrosine kinase-1/placental growth factor ratio for preeclampsia in Japan: a systematic review
by: Yamazaki, T, et al.
Published: (2020)

CORRELATION BETWEEN FMS-LIKE TYROSINE KINASE-1 (SFLT-1) CELL-FREE MESSENGER RNA EXPRESSION AND FMS-LIKE TYROSINE KINASE-1 (SFLT-1) PROTEIN LEVEL IN SEVERE PREECLAMPSIA AND NORMAL PREGNANCY
by: Jeffry Iman Gurnadi, et al.
Published: (2015-09-01)

Soluble Fms-like tyrosine cinase 1 (sFLt-1) and antibody against AT1-receptor in preclempsia a comparison in a blind study design
by: Verlohren, S, et al.
Published: (2008)

Meta-analysis and systematic review to assess the role of soluble FMS-like tyrosine kinase-1 and placenta growth factor ratio in prediction of preeclampsia: The SaPPPhirE Study.
by: Agrawal, S, et al.
Published: (2017)

Soluble Fms-Like Tyrosine Kinase-1 (Sflt-1) and Autoantibodies Against the AT1-Receptor in Preeclampsia in a Matched Pair, Blinded, Study Design.
by: Verlohren, S, et al.
Published: (2008)

The soluble VEGF receptor sFlt-1 contributes to endothelial dysfunction in IgA nephropathy.
by: Yaling Zhai, et al.
Published: (2020-01-01)

Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia.
by: Natalie J Hannan, et al.
Published: (2018-01-01)

sFlt-1, PlGF, sFlt-1/PlGF ratio and uterine artery Doppler for preeclampsia diagnostics
by: Viktorija Tarasevičienė, et al.
Published: (2016-01-01)

Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia.
by: Zeisler, H, et al.
Published: (2016)

Novel Ratio Soluble Fms-like Tyrosine Kinase-1/Angiotensin-II (sFlt-1/ANG-II) in Pregnant Women Is Associated with Critical Illness in COVID-19
by: Salvador Espino-y-Sosa, et al.
Published: (2021-09-01)

Maternal and Perinatal Outcomes Associated With Extremely High Values for the sFlt‐1 (Soluble fms‐Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio
by: Cecilia Villalaín, et al.
Published: (2020-04-01)

Elevated soluble VEGF receptor sFlt-1 correlates with endothelial injury in IgA nephropathy.
by: Ya-Ling Zhai, et al.
Published: (2014-01-01)

Ruling out preeclampsia in the next 4 weeks using a soluble fms-like tyrosine kinase 1/placental growth factor ratio ≤38: secondary analysis of the Interventional Study on Prediction of Preeclampsia/Eclampsia in Women With Suspected Preeclampsia
by: Cerdeira, AS, et al.
Published: (2021)

Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia
by: Park So-Yeon, et al.
Published: (2008-07-01)

Intraperitoneal Injection of High Tumor Necrosis Factor (TNF- α ) Serum Increase Soluble Fms-like Tyrosine Kinase 1 (sFlt-1) and Blood Pressure of Pregnant Mice
by: Bramantyo Aji Wicaksono, et al.
Published: (2015-05-01)

Efficiency of sFlt-1/PlGF Ratio in Preeclampsia Diagnosis
by: Anca-Florina Tataru-Copos, et al.
Published: (2022-09-01)

Predicting Preeclampsia Pregnancy Termination Time Using sFlt-1
by: Hiroaki Tanaka, et al.
Published: (2022-06-01)

The feasibility of soluble Fms-Like Tyrosine kinase-1 (sFLT-1) and Placental Growth Factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia.
by: Nurul Afzan Aminuddin, et al.
Published: (2022-01-01)

Circulating soluble fms-like tyrosine kinase-1 is placentally derived in normal pregnancy: first in vivo evidence
by: Cerdeira, AS, et al.
Published: (2019)

The ratio of soluble fms–like tyrosine kinase 1 to placental growth factor predicts time to delivery and mode of birth in patients with suspected preeclampsia- a secondary analysis of the INSPIRE trial
by: Palma Dos Reis, CR, et al.
Published: (2024)

Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa
by: Na Wang, et al.
Published: (2021-01-01)

Soluble fms-like tyrosine kinase-1-to-placental growth factor ratio and time to delivery in women with suspected preeclampsia
by: Zeisler, H, et al.
Published: (2016)

ADENOVIRAL DELIVERY OF SOLUBLE VEGF RECEPTOR (sFLT-1) ABROGATES DISEASE ACTIVITY IN MURINE COLLAGEN INDUCED ARTHRITIS
by: Afuwape, A, et al.
Published: (2002)

Placental sFLT1 is associated with complement activation and syncytiotrophoblast damage in preeclampsia
by: Ai-ris Yonekura Collier, et al.
Published: (2019-07-01)

A simple detection method for the serum sFLT1 protein in preeclampsia
by: Masabumi Shibuya, et al.
Published: (2021-10-01)

Soluble Fms-Like Tyrosine Kinase-1 Alters Cellular Metabolism and Mitochondrial Bioenergetics in Preeclampsia
by: Lissette C. Sánchez-Aranguren, et al.
Published: (2018-03-01)

Transcriptionally Active Syncytial Aggregates in the Maternal Circulation May Contribute to Circulating Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia
by: Rajakumar, A, et al.
Published: (2012)

Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis.
by: Afuwape, A, et al.
Published: (2003)

Predictive Value Analysis of Serum sFlt-1 and PLGF Levels/Ratio in Preeclampsia
by: Shuyuan Xue, et al.
Published: (2022-09-01)

One step closer to a cure for preeclampsia? Boosting the natural affinity of VEGF (vascular endothelial growth factor) to sFlt (soluble fms-like tyrosine kinase)-1

Similar Items

Similar Items